USFDA nod for Natco’s renal disease drug 

Hyderabad: Natco Pharma has received an approval from the US FDA to market Lanthanum Carbonate chewable tablets used in treatment of patients with end stage renal disease. The drug major in a communique to BSE said that USFDA have given a final approval for marketing Lanthanum Carbonate chewable tablets in various strengths.

“The product, as the first generic, will be launched shortly in the USA market,” Natco Pharma said. Natco’s Lanthanum Carbonate strengths are generic equivalent of Shire Development LLC’s Fosrenol chewable tablets and are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).